In 2015, there were about 1,600 enterprises above scale in Chinese patent medicine industry in China. The total asset of the industry was RMB596 billion, rising by about 10%. The sakes revenue was RMB615 billion, rising by 6%. The total profit was RMB67 billion, rising by 13%.

In 2015, the output of Chinese patent medicine in China was 3.76 million tonnes, rising by 2%. At present, Chinese medicine has stepped into a road of virtuous cycle, namely from prevention to cure and then from cure to prevention.

Since China has invested more in Chinese medicine industry, the industry has been developing to modernization. Modern Chinese patent medicines have better quality and clinical effect, and it has “special effect” to some disease.

Chinese patent medicine is one of the three pillar industries of Chinese medicine industry. For a better construction and development, the government has published a series of supporting policies, which will make explosion increase in Chinese patent industry for the next few years.

Figure No.	Figure Title
Figure 1	GDPs of China, 2011-2016
Figure 2	Fixed asset investments in China, 2011-2016
Figure 3	Total retail sales of consumer goods in China, 2011-2016
Figure 4	Per capita disposable incomes in China, 2011-2016
Figure 5	Total values of import and export of China, 2011-2016
Figure 6	Populations of China, 2011-2015
Figure 7	Distribution of China population by ages at the end of 2015
Figure 8	Urbanization rates of China, 2011-2015
Figure 9	Numbers of above-scale Chinese patent medicine enterprises in China, 2011-2015
Figure 10	Debt ratios of Chinese patent medicine industry in China, 2011-2015
Figure 11	Gross profit rates of Chinese patent medicine industry in China, 2011-2015
Figure 12	Sales profit rates of Chinese patent medicine industry in China, 2011-2015
Figure 13	Asset profit rates of Chinese patent medicine industry in China, 2011-2015
Figure 14	Turnovers of accounts receivable of Chinese patent medicine industry in China, 2011-2015
Figure 15	Turnovers of circulating asset of Chinese patent medicine industry in China, 2011-2015
Figure 16	Turnovers of total asset of Chinese patent medicine industry in China, 2011-2015
Figure 17	Outputs of Chinese patent medicines in China, 2011-2015
Figure 18	Regional output distribution of Chinese patent medicine in China 2015
Figure 19	Business proportions of Tasly Pharmaceutical Group Co., Ltd. in 2015
Figure 20	Business proportions of Tianjin Zhongxin Pharmaceutical Group Corporation Limited in 2015
Figure 21	Business proportions of Hunan Fangsheng Pharmaceutical Co., Ltd. in 2015
Figure 22	Business proportions of Shanghai Kaibao Pharmaceutical Co., Ltd. in 2015
Figure 23	Business proportions of Zhejiang Xinguang Pharmaceutical Limited Liability Company in 2014
Figure 24	Business proportions of Xi’an Wanlong Pharmaceutical Co., Ltd. in 2014
Figure 25	Business proportions of Buchang Pharmaceuticals in 2015
Figure 26	Business proportions of Teyi Pharmaceutical Co., Ltd. in 2015
Figure 27	Business proportions of Heilongjiang ZBD Pharmaceutical Co., Ltd. in 2015
Figure 28	Business proportions of Lanzhou Foci Pharmaceutical Co., Ltd. in 2015

Table No.	Table Title
Table 1	GDPs and distributions of China, 2014-2016
Table 2	Related polices to Chinese patent medicine industry in China
Table 3	Population distribution of China in 2015
Table 4	Costs on medical care of urban residents in China, 2011-2015
Table 5	Costs on medical care of rural residents in China, 2011-2015
Table 6	Numbers of health institutions in China, 2013-2016
Table 7	Total assets of Chinese patent medicine industry in China, 2011-2015
Table 8	Sales revenues of Chinese patent medicine industry in China, 2011-2015
Table 9	Total profits of Chinese patent medicine industry in China, 2011-2015
Table 10	Revenues of Tasly Pharmaceutical Group Co., Ltd. by industries and products in 2015
Table 11	Revenues and profits of Tasly Pharmaceutical Group Co., Ltd., 2012-2016
Table 12	Regional revenues of Tasly Pharmaceutical Group Co., Ltd. in 2015
Table 13	Revenues of Tianjin Zhongxin Pharmaceutical Group Corporation Limited by products from Jan. to Sep. in 2016
Table 14	Revenues and profits of Tianjin Zhongxin Pharmaceutical Group Corporation Limited, 2012-2016
Table 15	Revenues of Hunan Fangsheng Pharmaceutical Co., Ltd. by industries and products in 2015
Table 16	Revenues and profits of Hunan Fangsheng Pharmaceutical Co., Ltd., 2012-2016
Table 17	Regional revenues of Hunan Fangsheng Pharmaceutical Co., Ltd. in China 2015
Table 18	Revenues of Shanghai Kaibao Pharmaceutical Co., Ltd. by industries and products in 2015
Table 19	Revenues and profits of Shanghai Kaibao Pharmaceutical Co., Ltd., 2012-2016
Table 20	Regional revenues of Shanghai Kaibao Pharmaceutical Co., Ltd. in 2015
Table 21	Revenues of Zhejiang Xinguang Pharmaceutical Limited Liability Company by products, 2012-2014
Table 22	Revenues and profits of Zhejiang Xinguang Pharmaceutical Limited Liability Company, 2012-2014
Table 23	Revenues of Xi’an Wanlong Pharmaceutical Co., Ltd. by products, 2012-2014
Table 24	Revenues and profits of Xi’an Wanlong Pharmaceutical Co., Ltd., 2012-2014
Table 25	Revenues of Buchang Pharmaceuticals by products, 2013-2016
Table 26	Revenues and profits of Buchang Pharmaceuticals, 2013-2016
Table 27	Revenues of Teyi Pharmaceutical Co., Ltd. by industries and products in 2015
Table 28	Revenues and profits of Teyi Pharmaceutical Co., Ltd., 2012-2016
Table 29	Regional revenues of Teyi Pharmaceutical Co., Ltd. in 2015
Table 30	Revenues of Heilongjiang ZBD Pharmaceutical Co., Ltd., by industries and products in 2015
Table 31	Revenues and profits of Heilongjiang ZBD Pharmaceutical Co., Ltd., 2012-2016
Table 32	Regional revenues of Heilongjiang ZBD Pharmaceutical Co., Ltd. in 2015
Table 33	Revenues of Lanzhou Foci Pharmaceutical Co., Ltd. by industries and products in 2015
Table 34	Revenues and profits of Lanzhou Foci Pharmaceutical Co., Ltd., 2012-2016